anamorelin inn developmental code names also known anamorelin hydrochloride usan jan nonpeptide orallyactive centrallypenetrant selective agonist ghrelingrowth hormone secretagogue receptor ghsr appetiteenhancing anabolic effects development helsinn healthcare sa treatment cancer cachexia anamorelin significantly increases plasma levels growth hormone gh insulinlike growth factor insulinlike growth factorbinding protein humans without affecting plasma levels prolactin cortisol insulin glucose adrenocorticotropic hormone acth luteinizing hormone lh folliclestimulating hormone fsh thyroidstimulating hormone addition anamorelin significantly increases appetite overall body weight lean body mass muscle increases body weight correlating directly increases plasma february anamorelin completed phase iii clinical trials treatment cancer cachexia anorexia associated nonsmallcell lung may european medicines agency recommended refusal marketing authorisation medicinal product intended treatment anorexia cachexia unintended weight loss patients nonsmall cell lung cancer helsinn requested reexamination initial opinion considering grounds request european medicines agency reexamined opinion confirmed refusal marketing authorisation september european medicines agency concluded studies show marginal effect anamorelin lean body mass proven effect hand grip strength patients quality life addition following inspection clinical study sites agency considered safety data medicine recorded adequately therefore agency opinion benefits anamorelin outweigh hormonal preparation article stub help wikipedia expanding httpsenwikipediaorgwikianamorelin